Previous close | 0.1600 |
Open | 0.1500 |
Bid | 0.0100 |
Ask | 0.7000 |
Strike | 1,100.00 |
Expiry date | 2024-06-21 |
Day's range | 0.1500 - 0.1600 |
Contract range | N/A |
Volume | |
Open interest | 285 |
The stock market is at highs with Apple's AI push, the Fed rate "dot-plot" and the Tesla shareholder meeting headlining key events and news.
Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. The efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on liver histology
Eli Lilly stock is climbing higher ahead of an FDA meeting to discuss its Alzheimer's treatment. Is LLY stock a buy right now?